Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Tomer Kariv
AddedMar 31, 2024
UpdatedMay 31, 2026
Tomer Kariv

Tomer Kariv

Co-Founder & CEO, Pontifax

Crunchbase

Tomer Kariv's Career

Pontifax
Pontifax

Herzliya, Tel Aviv District, IL

Co-Founder & CEO· C-Suite · Management
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals

Watertown, MA, US

Board Member· Board
Keros Therapeutics
Keros Therapeutics

Lexington, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Tomer Kariv's Career

Pontifax
Pontifax
Investment FirmInvestment Firm422004Herzliya, Tel Aviv District, IL
Co-Founder & CEO· C-Suite · Management

Leadership at Pontifax

Arie BelldegrunArie BelldegrunBoard Member
Ran NussbaumRan NussbaumCo-Founder
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals
Public162013Watertown, MA, US
Board Member· Board

Leadership at Eloxx Pharmaceuticals

Sumit AggarwalSumit AggarwalBoard Member
Keros Therapeutics
Keros Therapeutics
Public$230M1052015Lexington, MA, US
Board Member· Board

Leadership at Keros Therapeutics

Jasbir SeehraJasbir SeehraCo-Founder
Carl L. GordonCarl L. GordonBoard Member
Mary Ann GrayMary Ann GrayBoard Member
Paul YuPaul YuBoard Member

Similar to Keros Therapeutics

KereosKereosSt. Louis, MO, USImaging Agents, Therapeuticsest. 1999KereosSt. Louis, MO, US · est. 1999

Kereos: A biotech firm innovating molecular imaging agents for cancer and heart disease treatment.

Series B · $27.2M9
Kymera TherapeuticsKymera TherapeuticsWatertown, MA, USDrugsest. 2017Kymera TherapeuticsWatertown, MA, US · est. 2017

Kymera Therapeutics, a global biopharmaceutical firm, innovates drugs for untreatable acute and chronic diseases.

Public · $879M167
Kestrel TherapeuticsKestrel TherapeuticsWayland, MA, USCancer Treatmentest. 2020Kestrel TherapeuticsWayland, MA, US · est. 2020

Kestrel Therapeutics: Pioneering RAS cancer treatment solutions through medical research.

Series A · $40M6
Kezar Life SciencesKezar Life SciencesSouth San Francisco, CA, USMedicines, Therapeuticsest. 2015Kezar Life SciencesSouth San Francisco, CA, US · est. 2015

Kezar Life Sciences, a biotech firm, develops molecular therapeutics for autoimmune disorders in California.

Public · $123M84

Tomer Kariv's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakHaeil YiHaeil YiCo-Founder · DunamuLee Sirg-OoLee Sirg-OoCEO · Dunamu

People Similar to Tomer Kariv

Greg WilliamsGreg WilliamsBoard Member · Swag'R Digital MediaUri LevineUri LevineFounder · The Founders KitchenMichael ChoiMichael ChoiCo-Founder · MarcoPoloBenjamin CardarelliBenjamin CardarelliCo-Founder · CrossFundJim TananbaumJim TananbaumBoard Member · Fulcrum TherapeuticsChristian SchroederChristian SchroederCo-Founder · 10x Value Partners